300 Third Street, First Floor
About Editas Medicine
Editas Medicine is a transformative genome editing company founded by world leaders in the fields of genome editing, protein engineering, and molecular and structural biology, with specific expertise in CRISPR/Cas9 and TALENs technologies.
The company's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products.
Editas was founded in 2013 with $43 million in Series A venture capital financing led by leading health care venture capital firms Flagship Ventures, Polaris Partners and Third Rock Ventures with participation from Partners Innovation Fund.
Founders: Feng Zhang, Jennifer Doudna, George Church, J. Keith Joung, and David Liu
CEO: Karine Bosley
CFO: Andrew Hack
COO: Alexandra Glucksmann
CTO: Vic Myer
Please click here for Editas Medicine job opportunities.
FOLLOW EDITAS MEDICINE:
Tweets by Editas Medicine
124 articles with Editas Medicine
Allergan and Editas Medicine Announce Exercise of Options to Jointly Develop CRISPR Genome Editin...
8/6/2018Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that Allergan's wholly-owned subsidiary, Allergan Pharmaceuticals International Limited (Allergan), has exercised its option to develop an...
NuProbe Global announced today the formation of its Scientific Advisory Board (SAB) with genomics pioneers George M. Church, Ph.D. and David R. Walt, Ph.D.
Shares of CRISPR Therapeutics (-8 percent), Editas Medicines (-5 percent) and Intellia Therapeutics (-6.7 percent) are all plunging following the release of a report that claimed CRISPR-Cas9 gene editing may cause some dangerous side effects.
6/26/2018The general consensus is that only about seven to nine percent of chief executive roles in biotech are filled by women. As low as that sounds, it’s better than in the Fortune 500, where only about 4.2 percent are led by female chief executives.
The U.S. Patent and Trademark Office (USPTO) granted Emmanuelle Charpentier, co-founder of ERS Genomics, the University of California and University of Vienna, their first U.S. patent covering the use of CRISPR/Cas9 for gene editing.
With $87 Million in Hand, Beam Therapeutics Launches to Fight Disease with CRISPR Base Editing Te...
5/14/2018Beam Therapeutics, a new precision genetic medicines company, launched this morning with $87 million in a Series A funding round backed by F-Prime Capital Partners and ARCH Venture Partners.
All that is lacking from the likely drama surrounding patent battles over CRISPR technology in the U.S. Court of Appeals today is Michael Buffer’s cry of “Let’s get ready to rumble.”
A look at three small biotech companies that appear to be leading the CRISPR race.
The companies established this collaboration to explore the delivery of genome editing medicines to treat up to five inherited retinal diseases.
A look at a biotech company that represents a solid trend in the industry.
Editas Medicine Reports Data Supporting Multiple Approaches to Create Treatments for Sickle Cell Disease and Beta-Thalassemia
Experiments support opportunities to develop best-in-class therapies for hemoglobinopathies.
Morgan Stanley is acting as sole book running manager for the offering.
All of the shares in the offering are to be sold by Editas Medicine.
It's not always easy to see when a company is a "disruptor," which is to say, that it causes a paradigm shift in how an industry operates.
Cash, cash equivalents, and marketable securities at September 30, 2017, were $295.7 million, compared to $199.9 million at September 30, 2016.
The hearing will focus on the therapeutic potential and ethical issues of using CRISPR technology to alter human DNA.
The conference call will be held on Tuesday, November 7, 2017, at 5:00 p.m. ET to discuss a corporate update and results for the third quarter of 2017.
Editas Medicine Demonstrates Dose-Dependent, In Vivo Editing With EDIT-101 in CEP290 Transgenic Mice
Productive gene editing rates with EDIT-101 were stable over six months in transgenic mice.
Editas Medicine Initiates Clinical Natural History Study To Evaluate Patients With Leber Congenital Amaurosis Type 10 (LCA10)